Neurological Disease

N-Desmethyl rosiglitazone (SB 237216) is a metabolite of Rosiglitazone (HY-17386), generated through demethylation by the cytochrome P450 enzyme system in liver microsomes. It retains partial PPARγ agonist activity and supports studies on the metabolism and pharmacokinetics of Rosiglitazone (HY-17386).

Lazertinib (Standard) is the analytical standard of Lazertinib (HY-109061). This product is intended for research and analytical applications. Lazertinib (YH25448) is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine K_inase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib can be used in the study of non-small cell lung cancer.

2-Aminotetralin is a potent and selective serotonin 5-HT₁ agonist. 2-Aminotetralin exhibits high affinity (K_i≤25 nM) and at least 50-fold stereoselective preference at 5-HT_1A, 5-HT_1B, and 5-HT_1D receptors.

N,N-didesmethyl AH 7921 is structurally categorized as an opioid metabolite and is a metabolite of AH 7921.

(Rac)-Preclamol ((±)-3-PPP) is the racemate of (R)-Preclamol (HY-145454A) and Preclamol (HY-145454A). (Rac)-Preclamol exhibits autoreceptor agonistic activity at dopamine Dopamine Receptor, with almost no effect on postsynaptic dopamine receptors. (Rac)-Preclamol inhibits spontaneous motor activity and the γ-butyrolactone-induced increase in mature striatal Tyrosine Hydroxylase activity. (Rac)-Preclamol can be used in research related to neurological diseases.

Kaurenoic acid (Standard) is the analytical standard of Kaurenoic acid. This product is intended for research and analytical applications. Kaurenoic acid is a diterpene from Sphagneticola trilobata, inhibits Inflammatory Pain by the inhibition of cytokine production and activation of the NO–cyclic GMP–PKG–ATP-sensitive potassium channel signaling pathway.

TP-024 (Standard) (FTBMT (Standard)) is the analytical standard of TP-024 (HY-101787). This product is intended for research and analytical applications. TP-024 (FTBMT), a chemical probe, is a selective GPR52 agonist with an EC₅₀ of 75 nM. TP-024 has antipsychotic and procognitive properties.

Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway.

Rubiadin (Standard) is the analytical standard of Rubiadin (HY-N0444). This product is intended for research and analytical applications. Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.

Enciprazine is an orally active non-benzodiazepine anxiolytic. Enciprazine acts as an agonist of 5-HT₁A receptor (5-HT₁AR) and an antagonist of α₁-adrenergic receptor (α1-adrenergic receptor) . Enciprazine induces drug-related electroencephalogram changes by reducing the average power of δ waves and θ waves, and increasing the average power of α waves and fast β waves. Enciprazine exhibits anti-aggressive activity, with only weak sedative and ataxic effects. Enciprazine regulates plasma corticosterone levels and activates the hypothalamic-pituitary-adrenal axis. Enciprazine can be used in research related to anxiety disorders, generalized anxiety syndrome and psychosis.

MEP-FUBICA is structurally categorized as a synthetic cannabinoid.

Azidothiorphan is an irreversible photoaffinity ligand and Endopeptidase 24.11 inhibitor, with a K_i value of 0.75 nM against Endopeptidase 24.11. Upon UV irradiation, Azidothiorphan binds to the active site of enkephalinase, resulting in irreversible loss of enzyme activity. Azidothiorphan produces long-lasting analgesic effects in mice. Azidothiorphan can be used in pain-related research.

WAY-213613 hydrochloride (Standard) is the analytical standard of WAY-213613 (hydrochloride) (HY-107523A). This product is intended for research and analytical applications. WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC₅₀ value of 85 nM. WAY-213613 can be used for the research of central nervous system.

Clobetasol is a glucocorticoid and Smoothened agonist that can cross the blood-brain barrier. Clobetasol induces Smo-dependent activation of the Shh signaling pathway and nuclear translocation of Gli1. Clobetasol promotes remyelination and reduces myelin loss in lesions of neuromyelitis optica (NMO). Clobetasol may cause adrenal suppression, cushingoid appearance, and local adverse reactions including dysgeusia, xerostomia, and gastroesophageal burning. Clobetasol can be used in research related to neurodegenerative diseases, oral lichen planus, mucous membrane pemphigoid, and neuromyelitis optica.

Desonide (Standard) is the analytical standard of Desonide. This product is intended for research and analytical applications. Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis.

CP-316819 (GPi 819) Standard is the analytical standard of CP-316819 (HY-108615). This product is intended for research and analytical applications. CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes.

JNJ-10258859 is a potent and selective phosphodiesterase type 5 inhibitor, with a K_i of 0.23 nM. JNJ-10258859 can be used for erectile dysfunction research.

H-89 (Standard) is the analytical standard of H-89 (HY-15979). This product is intended for research and analytical applications. H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein K_inase (protein K_inase A) with IC₅₀ of 48 nM and has weak inhibition on PKG, PKC, Casein K_inase, and others K_inases.

Neuroprotectin B is a cyclopeptide. Neuroprotectin B has the function of protecting chicken brain neuron culture from excitatory toxicity induced by glutamate and red alginate.

VU0650786 (Standard) is the analytical standard of VU0650786 (HY-108710). This product is intended for research and analytical applications. VU0650786 is a potent and selective CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 (mGlu3 NAM), with an IC₅₀ of 392 nM. VU0650786 has antidepressant and anxiolytic activity in rodents.